Navigation Links
New Report Defines Challenges for New Entrants in Key Rheumatology Markets
Date:4/7/2009

MedPredict's Rheumatology Thought Leader Panel Creates a 'Fantasy Formulary' For 2015

SCOTTSDALE, Ariz., April 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis, lupus, gout and psoriatic arthritis.

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted a thought exercise with four North American and four European rheumatologists. The purpose was to identify their "must have" branded and generic drugs for their real-world practices in the year 2015. This report outlines each panelist's "Fantasy Formulary," and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned.

"It is essential that drug developers consider the entire rheumatology practice when establishing their strategies going forward," according to Dr. Jeffrey Berk, MedPredict's president and one of the report's authors. "One key insight from our research is that drugs which will be beneficial across multiple indications are going to have an easier time getting on formulary."

The report will answer the following questions:

  • What are these thought leaders' top ten choices for their rheumatology practice in 2015?
  • How do their choices differ by geography, and why?
  • How will the availability of biosimilars for substitution of first generation biologics impact the environment for new entrants?
  • What is the preferred anti-TNF drug, and why?
  • Where will new mechanistic approaches, such as Jak and Syk inhibitors, IL-17, anti-B-cell, and others fit in the rheumatologist's armamentarium?

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen, Amgen/Wyeth, Biogen Idec, Bristol-Myers Squibb, Can-Fite, Centocor, Centocor/Schering-Plough, Chelsea, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, J&J/Alza, Lilly, Medarex, Merck, Merck Serono/ZymoGenetics, Mitsubishi Tanabe, Neovacs, Nitec/SkyePharma, Novartis, Pozen/AstraZeneca, Rigel, Roche, Roche/Chugai, Roche/Genentech/Biogen Idec, Sanofi-Aventis, Savient, Takeda, UCB, Vertex, and Wyeth/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pain in the ICU report suggests comprehensive approach
2. Photos: Report Shows Youth Health Educators Reach More Poor Teens with a Message of Living Healthy Lives!
3. Chronic Pain Sufferers Report Relief: DRJ Group Teams With Adult Foster Care Facilities to Evaluate Effectiveness of Stopain Topical Analgesic
4. Hazardous Health Plans: Consumer Reports Investigation Finds Serious Gaps in Individual Health Insurance Policies
5. Consumer Reports Survey: Hands-On Therapies Among Top-Rated Treatments for Back Pain
6. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
7. MGT Capital Investments, Inc. Reports Fiscal 2008 Financial Results and Provides an Update on Recent Developments
8. IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification
9. Allscripts Reports Fiscal 2009 Third Quarter Results
10. J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members
11. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: